Login Register Cart 0
Generic placeholder image

Current Molecular Medicine

Editor-in-Chief

ISSN (Print): 1566-5240
ISSN (Online): 1875-5666

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

TPD52 is a Potential Prognostic Biomarker and Correlated with Immune Infiltration: A Pan-cancer Analysis

Author(s): Lu Miao*, Li Jing, Buze Chen, Tian Zeng and Youguo Chen*

Volume 24, Issue 11, 2024

Published on: 16 October, 2023

Page: [1413 - 1425] Pages: 13

DOI: 10.2174/0115665240260252230919054858

Price: $65

Abstract

Background: Some tumors have a poor prognosis regarding TPD52 (tumor protein D52). This study aims to explore TPD52's role in the cancer process from a pan-cancer perspective.

Methods: A pan-cancer analysis was conducted to investigate how TPD52 may be involved in cancer as well as its association with prognosis.

Results: A variety of human cancers express TPD52 abnormally and correlate with clinical stage. There was a significant association between low expression of TPD52 and poor survival in BRCA, KIRP, LAML, LIHC, UCEC, and UVM. TPD52 alterations were most frequently amplified in pan-cancer. The co-occurrence of 10 genes alterations was found in the TPD52 altered group. There was a significant association between TPD52 expression and MSI in four cancer types and TMB in twelve cancer types. There was a significant correlation between TPD52 expression and immunerelated cell infiltration. A significant correlation was found between TPD52 expression in many tumor types and 8 immune checkpoint genes. There were signaling pathways involved in pan-cancer caused by TPD52, including endocytosis, Fc gamma Rmediated phagocytosis, and so on. TPD52 may be involved in chemotherapy and chemoresistance.

Conclusion: The TPD52 gene may be important for human cancer treatment.

« Previous Next »
[1]
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA Cancer J Clin 2021; 71(3): 209-49.
[http://dx.doi.org/10.3322/caac.21660] [PMID: 33538338]
[2]
Chen J, Mai H, Chen H, Zhou B, Hou J, Jiang DK. Pan-cancer analysis identified C1ORF112 as a potential biomarker for multiple tumor types. Front Mol Biosci 2021; 8: 693651.
[http://dx.doi.org/10.3389/fmolb.2021.693651] [PMID: 34490347]
[3]
Zhong A, Chen T, Zhou T, Zhang Z, Shi M. TPD52L2 Is a prognostic biomarker and correlated with immune infiltration in lung adenocarcinoma. Front Pharmacol 2021; 12: 728420.
[http://dx.doi.org/10.3389/fphar.2021.728420] [PMID: 34744715]
[4]
Byrne JA, Mattei MG, Basset P. Definition of the tumor protein D52 (TPD52) gene family through cloning of D52 homologues in human (hD53) and mouse (mD52). Genomics 1996; 35(3): 523-32.
[http://dx.doi.org/10.1006/geno.1996.0393] [PMID: 8812487]
[5]
Byrne JA, Frost S, Chen Y, Bright RK. Tumor protein D52 (TPD52) and cancer-oncogene understudy or understudied oncogene? Tumour Biol 2014; 35(8): 7369-82.
[http://dx.doi.org/10.1007/s13277-014-2006-x] [PMID: 24798974]
[6]
Choschzick M, Lassen P, Lebeau A, et al. Amplification of 8q21 in breast cancer is independent of MYC and associated with poor patient outcome. Mod Pathol 2010; 23(4): 603-10.
[http://dx.doi.org/10.1038/modpathol.2010.5] [PMID: 20139910]
[7]
Chen Y, Peng C, Tan W, Yu J, Zayas J, Peng Y, et al. Tumor protein D52 (TPD52) affects cancer cell metabolism by negatively regulating AMPK. Cancer Med 2022; 12(1): 488-99.
[PMID: 35666017]
[8]
Wang Y, Fang J, Gu F. MiR-125b-5p/TPD52 axis affects proliferation, migration and invasion of breast cancer cells. Mol Biotechnol 2022; 64(9): 1003-12.
[http://dx.doi.org/10.1007/s12033-022-00475-3] [PMID: 35320453]
[9]
Li J, Li Y, Liu H, Liu Y, Cui B. The four-transmembrane protein MAL2 and tumor protein D52 (TPD52) are highly expressed in colorectal cancer and correlated with poor prognosis. PLoS One 2017; 12(5): e0178515.
[http://dx.doi.org/10.1371/journal.pone.0178515] [PMID: 28562687]
[10]
Cui X, Zhang X, Liu M, et al. A pan-cancer analysis of the oncogenic role of staphylococcal nuclease domain-containing protein 1 (SND1) in human tumors. Genomics 2020; 112(6): 3958-67.
[http://dx.doi.org/10.1016/j.ygeno.2020.06.044] [PMID: 32645525]
[11]
Musha K, Ge X, Ablikim N, Lu B, Chen C, Huang J. Comprehensive analysis of RELL2 as a potential biomarker associated with tumor immune infiltrating cells in a pan-cancer analysis. Dis Markers 2022; 2022: 1-21.
[http://dx.doi.org/10.1155/2022/5009512] [PMID: 35634441]
[12]
Yang D, Liu M, Jiang J, et al. Comprehensive analysis of DMRT3 as a potential biomarker associated with the immune infiltration in a pan-cancer analysis and validation in lung adenocarcinoma. Cancers 2022; 14(24): 6220.
[http://dx.doi.org/10.3390/cancers14246220] [PMID: 36551704]
[13]
Vivian J, Rao AA, Nothaft FA, et al. Toil enables reproducible, open source, big biomedical data analyses. Nat Biotechnol 2017; 35(4): 314-6.
[http://dx.doi.org/10.1038/nbt.3772] [PMID: 28398314]
[14]
Lin Z, Huang W, Yi Y, et al. LncRNA ADAMTS9-AS2 is a prognostic biomarker and correlated with immune infiltrates in lung adenocarcinoma. Int J Gen Med 2021; 14: 8541-55.
[http://dx.doi.org/10.2147/IJGM.S340683] [PMID: 34849000]
[15]
Han Q, Cui Z, Wang Q, Pang F, Li D, Wang D. Upregulation of OTX2-AS1 is associated with immune infiltration and predicts prognosis of gastric cancer. Technol Cancer Res Treat 2023; 22: 15330338231154091.
[http://dx.doi.org/10.1177/15330338231154091] [PMID: 36740995]
[16]
Yi W, Shen H, Sun D, et al. Low expression of long noncoding RNA SLC26A4 antisense RNA 1 Is an independent prognostic biomarker and correlate of immune infiltrates in breast cancer. Med Sci Monit 2021; 27: e934522.
[PMID: 34880202]
[17]
Liang W, Lu Y, Pan X, et al. Decreased expression of a novel lncRNA FAM181A-AS1 is associated with poor prognosis and immune infiltration in lung adenocarcinoma. Pharm Genomics Pers Med 2022; 15: 985-98.
[http://dx.doi.org/10.2147/PGPM.S384901] [PMID: 36482943]
[18]
Qiu W, Ding K, Liao L, Ling Y, Luo X, Wang J. Analysis of the expression and prognostic value of MSH2 in pan-cancer based on bioinformatics. BioMed Res Int 2021; 2021: 1-12.
[http://dx.doi.org/10.1155/2021/9485273] [PMID: 34859104]
[19]
Frost FG, Cherukuri PF, Milanovich S, Boerkoel CF. Pan cancer RNA seq data stratifies tumours by some hallmarks of cancer. J Cell Mol Med 2020; 24(1): 418-30.
[http://dx.doi.org/10.1111/jcmm.14746] [PMID: 31730267]
[20]
Tian Y, Bai F, Zhang D. HIF1α: A novel biomarker with potential prognostic and immunotherapy in pan-cancer. Oxid Med Cell Longev 2022; 2022: 1-17.
[http://dx.doi.org/10.1155/2022/1246267] [PMID: 35860430]
[21]
Gao H, Xu C, Liang J, et al. Pan-cancer analysis of oncogenic role of Programmed Cell Death 2 Like (PDCD2L) and validation in colorectal cancer. Cancer Cell Int 2022; 22(1): 100.
[http://dx.doi.org/10.1186/s12935-022-02525-x] [PMID: 35216602]
[22]
Kang P, Li Y, Hu Z, et al. Neuropilin-1 is a valuable biomarker for predicting response of advanced non-small cell lung cancer patients to hypofractionated radiotherapy and PD-1 blockade. Int Immunopharmacol 2022; 109: 108732.
[http://dx.doi.org/10.1016/j.intimp.2022.108732] [PMID: 35468364]
[23]
Thorsson V, Gibbs DL, Brown SD, et al. The immune landscape of cancer. Immunity 2018; 48(4): 812-830.e14.
[http://dx.doi.org/10.1016/j.immuni.2018.03.023] [PMID: 29628290]
[24]
Bonneville R, Krook MA, Kautto EA, Miya J, Wing MR, Chen HZ, et al. Landscape of microsatellite instability across 39 cancer types. JCO Precis Oncol 2017; 2017: PO.17.00073.
[25]
Chen J, Tang H, Li T, et al. Comprehensive analysis of the expression, prognosis, and biological significance of OVOLs in breast cancer. Int J Gen Med 2021; 14: 3951-60.
[http://dx.doi.org/10.2147/IJGM.S326402] [PMID: 34345183]
[26]
Zhang L, Li X, Zhang J, Xu G. Prognostic implication and oncogenic role of PNPO in pan-cancer. Front Cell Dev Biol 2022; 9: 763674.
[http://dx.doi.org/10.3389/fcell.2021.763674] [PMID: 35127701]
[27]
Wang J, Shi W, Miao Y, Gan J, Guan Q, Ran J. Evaluation of tumor microenvironmental immune regulation and prognostic in lung adenocarcinoma from the perspective of purinergic receptor P2Y13. Bioengineered 2021; 12(1): 6286-304.
[http://dx.doi.org/10.1080/21655979.2021.1971029] [PMID: 34494914]
[28]
Huang W, Fan L, Tang Y, Chi Y, Li J. A pan-cancer analysis of the oncogenic role of Integrin Beta4 (ITGB4) in human tumors. Int J Gen Med 2021; 14: 9629-45.
[http://dx.doi.org/10.2147/IJGM.S341076] [PMID: 34924769]
[29]
Lyu G, Li D, Li S, Ning C, Qin R. Genotoxic effects and proteomic analysis on Allium cepa var. agrogarum L. root cells under Pb stress. Ecotoxicology 2020; 29(7): 959-72.
[http://dx.doi.org/10.1007/s10646-020-02236-x] [PMID: 32507983]
[30]
Li D, Lyu G, Niu G, Wang X, Yin J. Interaction network of TaRHA2b of wheat (Triticum aestivum L.), based on high-throughput yeast two-hybrid screening. Appl Ecol Environ Res 2019; 13105-24.
[31]
Li DB, Lyu G, Lyu J, Niu H, Wang X. Cloning and characterization of a wheat ring finger gene tarha2b whose expression is upregulated by aba treatment. Appl Ecol Environ Res 2019; 17(4): 7495-510.
[http://dx.doi.org/10.15666/aeer/1704_74957510]
[32]
Liu Y, Xue J, Zhong M, Wang Z, Li J, Zhu Y. Prognostic prediction, immune microenvironment, and drug resistance value of collagen type I alpha 1 chain: From gastrointestinal cancers to pan-cancer analysis. Front Mol Biosci 2021; 8: 692120.
[http://dx.doi.org/10.3389/fmolb.2021.692120] [PMID: 34395525]
[33]
Li M, Wang X, Liu J, et al. Identification of core prognosis-related candidate genes in chinese gastric cancer population based on integrated bioinformatics. BioMed Res Int 2020; 2020: 1-14.
[http://dx.doi.org/10.1155/2020/8859826] [PMID: 33381592]
[34]
Lyu G, Li D, Xiong H, et al. Quantitative proteomic analyses identify STO/BBX24 -related proteins induced by UV-B. Int J Mol Sci 2020; 21(7): 2496.
[http://dx.doi.org/10.3390/ijms21072496] [PMID: 32260266]
[35]
Yang Y, Gu X, Li Z, et al. Whole-exome sequencing of rectal cancer identifies locally recurrent mutations in the Wnt pathway. Aging 2021; 13(19): 23262-83.
[http://dx.doi.org/10.18632/aging.203618] [PMID: 34642262]
[36]
He W, Dong S, Shen J, et al. Whole-genome sequencing identified novel mutations in a Chinese family with lynch syndrome. Front Oncol 2023; 13: 1036356.
[http://dx.doi.org/10.3389/fonc.2023.1036356] [PMID: 36874103]
[37]
Chen G, Luo D, Zhong N, et al. GPC2 Is a potential diagnostic, immunological, and prognostic biomarker in pan-cancer. Front Immunol 2022; 13: 857308.
[http://dx.doi.org/10.3389/fimmu.2022.857308] [PMID: 35345673]
[38]
Li Y, Sun Y, Li Z, Li S, Wu C. MiR-139-5p inhibits the development of gastric cancer through targeting TPD52. J Healthc Eng 2022; 2022: 1-10.
[http://dx.doi.org/10.1155/2022/4033373] [PMID: 35222884]
[39]
Shi P, Zhang X, Lou C, Xue Y, Guo R, Chen S. Hsa_circ_0084927 regulates cervical cancer advancement via regulation of the miR-634/TPD52 axis. Cancer Manag Res 2020; 12: 9435-48.
[http://dx.doi.org/10.2147/CMAR.S272478] [PMID: 33061631]
[40]
Zhao Z, Liu H, Hou J, et al. Tumor protein D52 (TPD52) inhibits growth and metastasis in renal cell carcinoma cells through the PI3K/Akt signaling pathway. Oncol Res 2017; 25(5): 773-9.
[http://dx.doi.org/10.3727/096504016X14774889687280] [PMID: 27983909]
[41]
Byrne JA, Maleki S, Hardy JR, et al. MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome. BMC Cancer 2010; 10(1): 497.
[http://dx.doi.org/10.1186/1471-2407-10-497] [PMID: 20846453]
[42]
Wang Y, Chen CL, Pan QZ, et al. Decreased TPD52 expression is associated with poor prognosis in primary hepatocellular carcinoma. Oncotarget 2016; 7(5): 6323-34.
[http://dx.doi.org/10.18632/oncotarget.6319] [PMID: 26575170]
[43]
Mao X, Xu J, Wang W, et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: New findings and future perspectives. Mol Cancer 2021; 20(1): 131.
[http://dx.doi.org/10.1186/s12943-021-01428-1] [PMID: 34635121]
[44]
Shi Q, Ma Y, Zhang X, Yin C. Circ_0060551 promotes the migration and invasion of cervical cancer by upregulating TPD52. Am J Reprod Immunol 2022; 88(3): e13586.
[http://dx.doi.org/10.1111/aji.13586] [PMID: 35716110]
[45]
Wang Y, Li M, Pan C, Huang H, Hu X, Liu J. Hsa_circ_0007637 facilitates nasopharyngeal carcinoma progression by sponging miR-636/TPD52 axis. Cancer Manag Res 2021; 13: 9439-52.
[http://dx.doi.org/10.2147/CMAR.S328207] [PMID: 35002322]
[46]
Zhang H, Li M, Zhang J, Shen Y, Gui Q. Exosomal Circ-XIAP promotes docetaxel resistance in prostate cancer by regulating miR-1182/TPD52 axis. Drug Des Devel Ther 2021; 15: 1835-49.
[http://dx.doi.org/10.2147/DDDT.S300376] [PMID: 33976535]
[47]
Kang JW, Kim Y, Lee Y, Myung K, Kim YH, Oh CK. AML poor prognosis factor, TPD52, is associated with the maintenance of haematopoietic stem cells through regulation of cell proliferation. J Cell Biochem 2021; 122(3-4): 403-12.
[http://dx.doi.org/10.1002/jcb.29869] [PMID: 33166425]
[48]
Liu S, Xi X. LINC01133 contribute to epithelial ovarian cancer metastasis by regulating miR-495-3p/TPD52 axis. Biochem Biophys Res Commun 2020; 533(4): 1088-94.
[http://dx.doi.org/10.1016/j.bbrc.2020.09.074] [PMID: 33036757]
[49]
Su D, Ji Z, Xue P, Guo S, Jia Q, Sun H. Long-noncoding RNA FGD5-AS1 enhances the viability, migration, and invasion of glioblastoma cells by regulating the miR-103a-3p/TPD52 axis. Cancer Manag Res 2020; 12: 6317-29.
[http://dx.doi.org/10.2147/CMAR.S253467] [PMID: 32848452]
[50]
Fu M, Chen CW, Yang LQ, et al. MicroRNA 103a 3p promotes metastasis by targeting TPD52 in salivary adenoid cystic carcinoma. Int J Oncol 2020; 57(2): 574-86.
[http://dx.doi.org/10.3892/ijo.2020.5069] [PMID: 32467999]
[51]
Wang Z, Li Y, Fan L, et al. Silencing of TPD52 inhibits proliferation, migration, invasion but induces apoptosis of pancreatic cancer cells by deactivating Akt pathway. Neoplasma 2020; 67(2): 277-85.
[http://dx.doi.org/10.4149/neo_2019_190404N295] [PMID: 31847526]
[52]
Kumamoto T, Seki N, Mataki H, et al. Regulation of TPD52 by antitumor microRNA-218 suppresses cancer cell migration and invasion in lung squamous cell carcinoma. Int J Oncol 2016; 49(5): 1870-80.
[http://dx.doi.org/10.3892/ijo.2016.3690] [PMID: 27633630]
[53]
Shahheydari H, Frost S, Smith BJ, Groblewski GE, Chen Y, Byrne JA. Identification of PLP2 and RAB5C as novel TPD52 binding partners through yeast two-hybrid screening. Mol Biol Rep 2014; 41(7): 4565-72.
[http://dx.doi.org/10.1007/s11033-014-3327-y] [PMID: 24604726]

Rights & Permissions Print Cite
© 2025 Bentham Science Publishers | Privacy Policy